VALNEVA (EPA:VLA) | Finanzwire

Basculer en Français

11012	Companies
241252	Keywords
169796	Articles
129860	Press releases

Home
Companies
VALNEVA

PRESS RELEASE

published on 09/13/2024 at 08:30, 2 years ago

Valneva Announces the Success of its Private Placement Raising approximately €60 Million
Valneva SE successfully raises approximately €60 million through a Private Placement, issuing 23,000,000 new ordinary shares. The funding will support the company's clinical programs and future growth, including the Shigella vaccine program

Private Placement Shareholders Funding Valneva SE Vaccine Program
BRIEF

published on 09/12/2024 at 22:10, 2 years ago

Valneva initiates a capital increase of 60 million euros

Euronext Paris Funding Capital Increase Valneva Vaccines
PRESS RELEASE

published on 09/12/2024 at 22:05, 2 years ago

Valneva Announces the Launch of a Private Placement of Ordinary Shares for Approximately 60 Million Euros
Valneva announces private placement of ordinary shares for 60 million Euros to fund clinical and pre-clinical programs, commercialization activities, and general corporate purposes. Accelerated book-building process underway

Private Placement Ordinary Shares Valneva Clinical Programs Accelerated Book-building
BRIEF

published on 09/03/2024 at 07:05, 2 years ago

Valneva and Pfizer: new positive data on Lyme disease vaccine

Valneva Phase 2 Pfizer Lyme Vaccine Positive Data
PRESS RELEASE

published on 09/03/2024 at 07:00, 2 years ago

Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate
Valneva and Pfizer announce positive Phase 2 booster results for Lyme disease vaccine candidate, VLA15-221, showing strong immune response and safety profile, advancing towards Phase 3 trials

Valneva Phase 2 Lyme Disease Vaccine Pfizer Immunogenicity
BRIEF

published on 08/30/2024 at 11:06, 2 years ago

Valneva SE Crosses Threshold

Voting Rights Stock Market Valneva SE Threshold Crossing Grimaud Group
BRIEF

published on 08/20/2024 at 16:06, 2 years ago

First Berlin Equity Research Reiterates Buy Rating for Valneva SE

Valneva Equity Research Market Undervaluation H1 Results Lyme Vaccine
PRESS RELEASE

published on 08/20/2024 at 16:01, 2 years ago

Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research GmbH updates research on Valneva SE (ISIN: FR0004056851) with a BUY recommendation and EUR 8.60 price target. H1 product sales slightly below consensus but gross margin improving. Valneva maintains full-year guidance

First Berlin Equity Research Buy Recommendation Valneva SE EUR 8.60 Price Target H1 Product Sales
BRIEF

published on 08/13/2024 at 07:05, 2 years 1 month ago

Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates

Financial Results Cash Position Revenue Guidance Valneva Vaccine Development
PRESS RELEASE

published on 08/13/2024 at 07:00, 2 years 1 month ago

Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates
Valneva reports first-half 2024 financial results as total revenues reach €70.8 million with net profit of €34.0 million. Company confirms full-year guidance and updates strategic pipeline expansion

Revenues Financial Results Net Profit Valneva Strategic Pipeline

Accesswire

Published on 09/17/2026 at 12:00, 55 minutes ago

Banyan Gold Intersects 1.05 g/t Gold over 52.8 metres and Bonanza-Grade Gold at Powerline Deposit, AurMac, Yukon, Canada
Published on 09/17/2026 at 10:00, 2 hours 55 minutes ago

Eagle Plains Reports Additional Results from Drilling at the Don Lake Uranium Project, Saskatchewan
Published on 09/16/2026 at 23:45, 13 hours 10 minutes ago

Galway Metals Settles Claim by Former Employee with Cash and Share Payments
Published on 09/16/2026 at 21:30, 15 hours 25 minutes ago

Torq Completes $1.7 Million Private Placement
Published on 09/16/2026 at 16:55, 20 hours ago

CORRECTION FROM SOURCE: SLAM Reports 1.60% Copper Equivalent Over 14.45 Meters in Hole GW26-33; Trenching Gold-Antimony Targets on Moose Lake Project

View all ACCESSWIRE

EQS Group

Published on 09/17/2026 at 12:29, 26 minutes ago

Electricity cloud market in transition: What options do customers have now?
Published on 09/17/2026 at 12:28, 27 minutes ago

Amundi Physical Metals plc: UK Final Terms
Published on 09/17/2026 at 12:22, 33 minutes ago

Amundi Physical Metals plc: Final Terms
Published on 09/17/2026 at 12:15, 40 minutes ago

BDStar Hosted 2026 Ecosystem Partner Conference in Munich, Germany
Published on 09/17/2026 at 12:01, 54 minutes ago

Alina Holdings PLC: 2026 Interim Results

Les Echos

Published on 09/16/2026 at 20:46, 16 hours 9 minutes ago

LNA SANTE : 2026 First Half Results
Published on 09/16/2026 at 17:45, 19 hours 10 minutes ago

5th edition of “On the way up” show
Published on 09/16/2026 at 17:45, 19 hours 10 minutes ago

Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 1 day 5 hours ago

bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
Published on 09/15/2026 at 18:00, 1 day 18 hours ago

Report on the Combined General Meeting of the 10th of September 2026

View all LES ECHOS COMFI WIRE